Cargando…
Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide
Advanced-stage peritoneal carcinomatosis is resistant to current chemotherapy treatment and, in the case of metastatic ovarian cancer, results in a devastating 15%–20% survival rate. Therapeutics that restore genes inactivated during oncogenesis are predicted to be more potent and specific than curr...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2004
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC340944/ https://www.ncbi.nlm.nih.gov/pubmed/14966535 http://dx.doi.org/10.1371/journal.pbio.0020036 |